Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03705065 · ClinicalTrials.gov registry record · Phase 4
Bupivacaine HCl PK and Safety in Augmentation Mammoplasty
A Phase 4 study, sponsored by Heron Therapeutics.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT03705065 is a Phase 4 study that has completed, run by Heron Therapeutics. The registered enrollment target is 30 participants.
The verdict
NCT03705065, a Phase 4 study, has completed, sponsored by Heron Therapeutics.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a Phase 4, randomized, open-label study of bupivacaine HCl administered either by instillation into the surgical site or by injection into the surgical site in subjects undergoing bilateral submuscular augmentation mammoplasty under general anesthesia.
Interventions
- DRUG Bupivacaine HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-09-19 |
| Est. Completion | 2018-11-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03705065
The ClinicalTrials.gov registry entry for NCT03705065 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Heron Therapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bupivacaine HCl is the first listed.
NCT03705065 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03705065 about?
NCT03705065 is a clinical study titled "Bupivacaine HCl PK and Safety in Augmentation Mammoplasty". This is a Phase 4, randomized, open-label study of bupivacaine HCl administered either by instillation into the surgical site or by injection into the surgical site in subjects undergoing bilateral submuscular augmentation mammoplasty under general anesthesia.
What is the current status of trial NCT03705065?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2018-09-19. Estimated completion is 2018-11-05.
What interventions are being tested in trial NCT03705065?
The interventions under investigation include: Bupivacaine HCl (DRUG).
Who is sponsoring clinical trial NCT03705065?
This trial is sponsored by Heron Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.